Adlai Nortye ANL
NASDAQ ANL
$15.78 +1.03 (+6.98%)
As of: Sep 4, 2026 · 3:55 PM EDT

Adlai Nortye (ANL) Non-Current Debt (2026)

Analysis

Adlai Nortye (ANL) Non-Current Debt (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 882.16 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 8.96 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 546.77 Mn
10 Adlai Nortye 500.08 Mn 268.19 Mn - 7.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 7.34 Mn